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Despite progress in the treatment of glioblastoma, more than 95% of patients suffering from this disease
still die within 2 years. Recent findings support the belief that cancer stem-like cells are responsible for
tumor formation and ongoing growth. Here a method combining lectin microarray and LC-MS/MS
was used to discover the cell surface glycoprotein markers of a glioblastoma-derived stem-like cell
line. Lectin microarray analysis of cell surface glycans showed that two galactose-specific lectins
Trichosanthes kirilowii agglutinin (TKA) and Peanut agglutinin (PNA) could distinguish the stem-like
glioblastoma neurosphere culture from a traditional adherent glioblastoma cell line. Agarose-bound
TKA and PNA were used to capture the glycoproteins from the two cell cultures, which were analyzed
by LC-MS/MS. The glycoproteins were quantified by spectral counting, resulting in the identification
of 12 and 11 potential glycoprotein markers from the TKA and PNA captured fractions respectively.
Almost all of these proteins were membrane proteins. Differential expression was verified by Western
blotting analysis of 6 interesting proteins, including the up-regulated Receptor-type tyrosine-protein
phosphatase zeta, Tenascin-C, Chondroitin sulfate proteoglycan NG2, Podocalyxin-like protein 1 and
CD90, and the down-regulated CD44. An improved understanding of these proteins may be important
for earlier diagnosis and better therapeutic targeting of glioblastoma.
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Introduction
Glioblastoma (GBM) is the most common malignant brain
tumor in adults. Even with advanced technology in surgery, in
vivo imaging, chemotherapy and radiotherapy, the overall
survival rate of GBM patients was only 17.7% at 1 year, and
3.3% at 2 years.1,2 Therefore, new strategies to treat GBM are
urgently needed. There is emerging evidence showing that
cancer stem cells within tumors are responsible for tumor
formation and ongoing growth.3 Cancer stem cells have the
ability to self-renew and drive tumorigenesis. The term cancer
stem cells reflects the “stem-like” properties of these cells.4
Such stem-like cells have been found in various solid tumors
such as breast, colon, head and neck, pancreas, and liver. Their
existence has also been demonstrated in brain tumors, includ-
ing GBM.5-8 We have demonstrated recently that Notch
pathway blockade depletes cancer stem-like cells in medullo-
blastoma and GBM.9-11 Therefore, new therapeutic methods
targeting cancer stem-like cells may bring hope for GBM
patients. Identification of markers of GBM stem cells will be
indispensable, since this may lead to earlier diagnosis and
improved therapeutic targeting of the disease. Most of the
known markers of cancer stem-like cells in solid tumors are
cell surface glycoproteins.4 The discovery of unique glycan
expression patterns on the surface of cancer stem-like cells is
an important step to identify novel surface glycoprotein mark-
ers of these cells.
The lectin microarray is a powerful tool to analyze the glycan
structures of glycoproteins.12-15 Recently, the technology has
been employed to study diverse cell processes by profiling cell
surface glycans of live cells.16-19 Using lectin microarray, Chen
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et al.17 evaluated glycan expression patterns on the surface of
several human breast cancer cell lines and observed significant
differences that related to cancer metastasis. Tao et al.19
analyzed the cell surface glycan signature of a human breast
cancer cell line MCF7 and found that the Lycopersicon escu-
lentum lectin (LEL) may be used as a biomarker of this cell
line. The investigation of cell surface glycan changes and the
discovery of specific glycan-binding lectins facilitate the iden-
tification of cell surface glycoprotein markers. In a recent study,
Lee et al.20 found that the Griffonia simplicifolia lectin II (GS
II) selectively bound to rat fibroblast cells but not to rat
endothelial cells, and therefore, they captured glycoproteins
from fibroblast cells using GS II and identified several glyco-
protein markers by LC-MS/MS. This work provided a useful
strategy that combined lectin microarray and mass spectrom-
etry to identify cell surface glycoprotein biomarkers.
In our work, high-sensitive fluorescence-assisted lectin mi-
croarrays were used to discover the cell surface glycan expres-
sion patterns of a human GBM stem-like cell line and a
traditional adherent GBM cell line as a control. Two lectins
Trichosanthes kirilowii agglutinin (TKA) and Peanut agglutinin
(PNA) which can distinguish the two cell lines were used to
capture the glycoproteins by affinity chromatography. The
LC-MS/MS analysis and label-free quantification resulted in
the identification of 12 and 11 potential glycoprotein markers
from the TKA and PNA captured fractions, respectively. Western
blotting analysis of 6 selected proteins confirmed the dif-
ferential expression. Future investigations of these proteins may
be helpful for identifying cancer stem-like cells from GBM.
Materials and Methods
Cell Culture. The human GBM-derived stem-like cell line
HSR-GBM1 was established by Vescovi and colleagues and
maintained in serum-free Neurocult medium (Stem Cell Tech-
nologies) supplemented with 20 ng/mL of both epidermal
growth factor (EGF) and fibroblast growth factor.6,21 Human
GBM cell line U373 was maintained in DMEM supplemented
with 10% fetal bovine serum. Cells growing exponentially were
harvested and washed twice with PBS.
Lectin Microarray. Sixteen lectins were used in this study.
The carbohydrate specificities of these lectins were listed in
Table 1. Each lectin was dissolved in PBS buffer (0.01 M
phosphate, 0.15 M NaCl, pH 7.4) to a concentration of 1 mg/
mL and printed on SuperAmine slides (Arrayit, Sunnyvale, CA)
using a piezoelectric noncontact printer (Nano plotter; GeSiM,
GmbH, Germany). Three spots per lectin were printed in each
block and 12 blocks were printed per slide. The total volume
of each spot was 2.5 nL, which resulted from spotting of 500
pL for 5 times. The slides were incubated in a humidity-
controlled incubator (>45% humidity) overnight to allow lectin
immobilization. After incubation, the slides were blocked with
1% BSA/PBS for 1 h and washed three times with PBST (0.1%
Tween 20 in PBS). U373 and HSR-GBM1 cells were labeled with
10 µM CFSE cell-tracing dye (Invitrogen, Carlsbad, CA) for 15
min in darkness. Each lectin blot on the slide was seeded with
2 × 105 CFSE-labeled cells in PBS with 0.5 mM CaCl2 and 1%
BSA. Cells were incubated with lectin microarrays at room
temperature for 40 min in darkness. After being washed with
PBS for 5 min, the slides were air-dried and scanned with a
microarray scanner (Genepix 4000A; Axon). Genepix 6.0 was
used to analyze the images.
Protein Extraction. Cells were washed once with PBS and
then suspended in 1 mL of lysis buffer (1% octyl--D-glucopy-
ranoside, 20 mM Tris-HCl, pH7.4, 150 mM NaCl, and 1%
protease inhibitor mixture (Sigma-Aldrich). The cells were
homogenized with 30 strokes in a Dounce glass homogenizer
with a tight-fitting pestle. The cell lysate was centrifuged at
40 000g for 30 min at 4 °C. The supernatant was collected and
the protein concentration was determined by the Bradford
method.22
Capture of Glycoproteins by Lectin Affinity. A Pierce
centrifuge column was packed with 1.5 mL of agarose-bound
PNA or TKA. The column was first washed with 3 vol of binding
buffer (20 mM Tris-HCl, pH7.4, 150 mM NaCl, 1 mM MgCl2, 1
mM CaCl2, and 1 mM MnCl2). Cell lysate containing 800 µg of
protein was diluted four times with binding buffer, and passed
through the column twice. The column was washed with 6 mL
of binding buffer to remove the nonspecific binding proteins.
Finally, the captured glycoproteins were released with 3 mL of
elution buffer (200 mM D-galactose in binding buffer, pH 7.4).
This step was repeated twice, and the eluted fractions were
pooled. For mass spectrometric analysis, the samples were
concentrated with Microcon YM-10 centrifugal filter devices,
reduced with 5 mM disulfide bond reducing agent Tris(2-
Table 1. Carbohydrate Specificities of the 16 Lectins Used for Lectin Microarraya
lectin abbreviation carbohydrate specificity source
Concanavalin A Con A Branched and terminal R-linked Man Vector Laboratories, Inc.
Ulex europaeus lectin I UEA-1 R-linked Fuc EY Laboratories, Inc.
Sambucus nigra lectin II SNA-2 GalNAc > Gal EY Laboratories, Inc.
Wheat germ agglutinin WGA GlcNAc EY Laboratories, Inc.
Sambucus nigra lectin SNA Neu5AcR (2-6)Gal Vector Laboratories, Inc.
Lycopersicon esculentum (Tomato) lectin LEL GlcNAc (prefers trimer and tetramer) Vector Laboratories, Inc.
Helix pomatia agglutinin HPA GalNAcR (Terminal) EY Laboratories, Inc.
Phaseolus vulgaris leucoagglutinin PHA-L Gal (1-4)GlcNAc (1-6)Man EY Laboratories, Inc.
Maackia amurensis lectin II MAL-2 Neu5AcR (2-3) Vector Laboratories, Inc.
Aleuria aurentia lectin AAL Terminal R-linked Fuc Vector Laboratories, Inc.
Lens culinaris agglutinin LCA R-linked mannose, FucR (1-6)GlcNAc Vector Laboratories, Inc.
Solanum tuberosum lectin STL GlcNAc (1-4)GlcNAc Vector Laboratories, Inc.
Bauhinia purpurea lectin BPL Gal (1-3)GalNAc, GalNAc Vector Laboratories, Inc.
Trichosanthes kirilowii TKA Gal EY Laboratories, Inc.
Peanut agglutinin PNA Gal (terminal) Vector Laboratories, Inc.
Soybean agglutinin SBA Terminal R- or -linked GalNAc Vector Laboratories, Inc.
a Man, mannose; Fuc, fucose; GalNAc, N-acetyl-D-galactosamine; Gal, galactose; GlcNAc, N-acetyl-D-glucosamine; Neu5Ac, N-acetylneuraminic acid (a
member of the sialic acid family).
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carboxyethyl)phosphine (TCEP) for 30 min, alkylated with 25
mM iodoacetamide for 20 min, and digested with trypsin and
PNGase F (Sigma-Aldrich).
Mass Spectrometry. The resulting tryptic peptides were
analyzed by LC-MS/MS using an LTQ mass spectrometer
(Thermo Finnigan, San Jose, CA). Chromatographic separation
of peptides was performed on a Paradigm MG4 micropump
system (Michrom Biosciences, Inc., Auburn, CA) equipped with
a C18 separation column (0.1 mm ×150 mm, C18 AQ particles,
5 µm, 120 Å, Michrom Biosciences, Inc., Auburn, CA). Peptides
were separated with a linear gradient of acetonitrile/water
containing 0.1% formic acid at a flow rate of 300 nL/min. A 90
min linear gradient from 5 to 40% acetonitrile was used. The
MS instrument was operated in positive ion mode. The ESI
spray voltage was set at 2.5 kV, and the capillary voltage at 30
V. The ion activation was achieved by utilizing helium at a
normalized collision energy of 35%. The data were acquired in
data-dependent mode using the Xcaliber software. For each
cycle of one full mass scan (range of m/z 400-2000), the three
most intense ions in the spectrum were selected for tandem
MS analysis, unless they appeared in the dynamic or mass
exclusion lists.
Western Blotting. Western blotting was performed es-
sentially as described before.23 Briefly, 20 µg of proteins from
HSR-GBM1, U373, U87, and T98G GBM cells were separated
by 4-20% SDS-PAGE and then transferred to PVDFmembranes
(Bio-Rad). U87 and T98G cell lysates were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). The membranes
were blocked for 2 h, and then incubated with various primary
antibodies for 4 h or overnight. Anti-NG2 and anti-CD44 were
obtained from Millipore (Billerica, MA); anti-PODXL and anti-
beta actin were from Abcam (Cambridge, MA); anti-CD90 and
anti-Tenascin-C were from Abnova (Taipei, China); anti-
Receptor-type tyrosine-protein phosphatase zeta (PTPRZ1) was
from Sigma-Aldrich (St. Louis, MO). After being washed three
times, the membranes were incubated with peroxidase-
conjugated IgG (H + L) for 1 h, washed three times, and
detected by Immobilon Western Chemiluminescent HRP Sub-
strate Kit (Millipore, Billerica, MA).
Data Analysis. All MS/MS spectra were searched against the
IPI database (IPI.human.v3.39). The search was performed
using SEQUEST algorithm version 27 incorporated in Bioworks
software version 3.1 SR1 (Thermo Finnigan). The search
parameters were as follows: (1) Fixed modification, Carbami-
domethyl of C; (2) variable modification, oxidation of M; (3)
allowing two missed cleavages; (4) peptide ion mass tolerance
1.50 Da; (5) fragment ion mass tolerance 0.0 Da; (6) peptide
charges+1,+2, and+3. The identified peptides were processed
by the Trans-Proteomic Pipeline (TPP).24 This software includes
both the PeptideProphet and ProteinProphet programs. The
database search results were first validated using the Pep-
tideProphet software, and then the peptides were assigned for
protein identification using the ProteinProphet software. In this
study, both the PeptideProphet probability score and the
ProteinProphet probability score were set to be higher than
0.9. This resulted in an overall false positive rate below 1%.25
We performed a comparative analysis between two cell lines
using the spectral counting method.26 Spectral counting is an
isotope label-free quantitation method to measure relative
abundance between proteins in a complex protein mixture. The
spectral count of individual proteins in both samples is
acquired after TPP analysis. Spectral count fold-change was
calculated as the ratio of the average spectral count for the
target protein. A 2-fold change was considered as a significant
difference between the two samples.
Results and Discussion
In the present work, we employed a method combining
lectin microarray, lectin affinity chromatography, and LC-MS/
MS to identify the cell surface glycoprotein markers for a GBM-
derived stem-like cell line. A diagram of the workflow of this
method is shown in Figure 1. The cell surface glycan expression
patterns of the stem-like cell line and a control cell line were
first explored by fluorescence-assisted lectin microarray, and
then two lectins TKA and PNA were selected to capture the
glycoproteins of the two cell lines by affinity chromatography.
Subsequently, the glycoproteins were identified by LC-MS/
MS and quantified by the spectral counting method. Finally,
the differentially expressed glycoproteins were further verified
by Western blotting analysis.
Illustration of Cell Surface Glycan Signatures by Lectin
Microarray. Lectin microarrays consisting of 16 lectins were
used to profile the surface glycan signature of the HSR-GBM1
neurosphere. As shown in Table 1, the carbohydrate specifici-
ties of the 16 lectins range extensively. The HSR-GBM1 cell line
is a GBM neurosphere cell line derived from human glioblas-
toma, and it displayed self-renewal and multilineage dif-
ferentiation features of neural stem cells.6 To investigate the
specific glycan patterns on the surface of this undifferentiated
cell line, a widely used traditional adherent GBM cell line U373
was chosen as a control. Figure 2A shows the binding patterns
of fluorescently labeled live cells to the lectin microarrays. Note
Figure 1. Workflow of lectin microarray and LC-MS/MS based
identification of cell surface glycoprotein markers. The HSR-
GBM1 and U373 live cells were first labeled with a fluorescent
dye CFSE, and then their cell surface glycan signatures were
profiled by lectin microarray. According to the binding patterns
of the two cell lines to the arrays, two lectins TKA and PNA were
selected for subsequent enrichment of glycoproteins by affinity
chromatography. The glycoproteins were identified by LC-MS/
MS and quantified by spectral counting. Finally, the changed
glycoproteins between the two cell lines were further validated
by Western blotting using four cell lines including the human
GBM-derived stem-like cell line HSR-GBM1 and three traditional
adherent human GBM cell lines U373, U87, and T98G.
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that the lectins TKA and PNA had much stronger binding
capacity to HSR-GBM1 cells than to U373 cells. Both of the
two lectins showed significant differences in fluorescent in-
tensities, while all the other 14 lectins showed similar intensities
(Figure 2B). This indicates TKA and PNA may be used to
distinguish the two cell lines.
Interestingly, both TKA and PNA have binding specificities
to -galactose (Table 1), which implies much higher expression
of galactosylated glycoproteins on the surface of the GBM-
derived stem-like cells as compared with traditional adherent
GBM cells. In a previous study, the galactosylated glycoproteins
were found to be expressed at higher level in glioma compared
with normal brains.27 Our findings suggest that the increase
of galactosylation in glioma brain tissues might be contributed
by cancer stem-like cells.
As shown in Table 1, the lectin Sambucus nigra lectin II
(SNA-2) also has binding specificity to -galactose, but it
primarily binds to -GalNAc. Therefore, we did not observe a
significant difference in fluorescent intensities for SNA-2 (Figure
2).
Preparation and Identification of Membrane Glycoproteins.
The binding patterns of TKA and PNA (Figure 2A) suggest that
their binding partners on the cell surface were potential
markers to distinguish the two cell lines. To discover these
glycoprotein markers, we applied lectin affinity chromatogra-
phy to capture glycoproteins from the HSR-GBM1 and U373
cells. A nonionic detergent, octyl--D-glucopyranoside, was
used to lyse cells. This class of detergents can improve the
solubility of membrane proteins.28,29 Agarose-bound TKA
and PNA were packed into a column to capture the glyco-
proteins. The eluted glycoproteins from three independent
enrichment experiments were digested and analyzed by
LC-MS/MS using an LTQ mass spectrometer. As an example,
Figure 3A shows a representative base peak chromatogram
of TKA captured fraction from HSR-GBM1 cells, and Figure
3B is a typical MS/MS spectrum.
The LTQ analysis resulted in the identification of 43 glyco-
proteins from TKA enriched fractions (Supplementary Table
S1) and 48 glycoproteins from PNA enriched fractions (Supple-
mentary Table S2), wherein 24 glycoproteins overlapped by the
two lectins. Consequently, a total of 67 glycoproteins were
identified from the two cell lines after PNA and TKA enrich-
ment. The detailed information of these glycoproteins is listed
in Supplementary Tables S3-S6. The difference observed in
protein identification from TKA and PNA enriched fractions
may result from the minor difference in the carbohydrate
specificities of the two lectins. Although TKA and PNA have
similar binding specificities to Gal, PNA can only bind to
terminal Gal, preferentially to terminal Gal (1-3)GalNAcR,
while TKA binds both terminal Gal and internal Gal (1-
3)GalNAcR.
The subcellular locations of the 67 glycoproteins were
annotated according to the UniProtKB database. A majority of
these glycoproteins were localized to the plasma membrane,
ER, and extracellular (Figure 4). Approximately 54% of these
glycoproteins were plasma membrane proteins.
Figure 2. Lectin microarray. (A) A typical lectin microarray image
depicts the binding patterns of two cell lines to the arrays of 16
lectins. Note that TKA and PNA lectins captured manymore HSR-
GBM1 cells than U373 cells. Each lectin was spotted in triplicate.
(B) Fluorescent intensities of the 16 lectins. Spot intensities were
the average of three values. *p < 0.05; ***p < 0.001.
Figure 3. LC-MS/MS analysis. (A) A representative base peak
chromatogram of TKA captured fraction from HSR-GBM1 cells.
(B) MS/MS spectrum of a peptide. The sequence of the peptide
was identified as VTSLTACLVDQSLR, which was from CD90
antigen.
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The number of glycoproteins identified after TKA and PNA
enrichment in this work was relatively low compared to
previous studies using other lectins to capture glycoproteins
from cells.29-31 To confirm that the difference was caused by
different lectins rather than our working system, we captured
glycoproteins from the HSR-GBM1 and U373 cells using
Concanavalin A (Con A) and analyzed these proteins by
LC-MS/MS, resulting in the identification of 83 and 100
glycoproteins from the two cell lines, respectively (Supplemen-
tary Tables S7 and S8). The numbers are comparable to that
from similar studies.30,31 The glycoproteins bound by either
TKA or PNA were less than half of those bound by Con A. This
indicates that both TKA and PNA have a more narrow specific-
ity than Con A.
A concern of the method used in this work was the
reproducibility. We used R2 values from linear regression for
spectral counts to investigate the reproducibility of three
replicate experiments. Here 33 and 40 glycoproteins were
identified from HSR-GBM1 cells after TKA and PNA enrich-
ment, respectively (Supplementary Tables S3 and S5), and the
average R2 values were around 0.7-0.8 for the three indepen-
dent experiments of the two lectins, which are comparable to
the values in some similar studies.32,33 This indicates that the
experiments from cell lysis to glycoprotein enrichment, and to
LTQ analysis were reproducible in the present work. Scatter
plots for each TKA or PNA experiment pairs of HSR-GBM1 cells
are available in Supplementary Figure S1. Consistent with the
lectin microarray analysis (Figure 2), less glycoproteins were
identified from U373 cells after TKA and PNA enrichment (only
23 and 10 glycoproteins were identified, respectively, see
Supplementary Tables S4 and S6), and most of the spectral
counts for individual proteins were less than 5. Therefore, the
U373 data sets were not suitable to evaluate the reproducibility.
Differentially Expressed Glycoproteins Analyzed by the
Label-Free Spectral Counting Method. The glycoproteins
identified by LC-MS/MS were analyzed by the spectral count-
ing method to quantify the relative protein abundance.26,34 As
a result, 12 differentially expressed glycoproteins between HSR-
GBM1 and U373 cells were identified from the TKA enriched
fractions (Table 2), and 11 differentially expressed glycoproteins
were identified from the PNA enriched fractions (Table 3),
wherein 5 proteins overlapped. As shown in Tables 2 and 3, a
majority of these proteins were membrane proteins, and a large
part of them were CD antigens. Note that most of these
glycoproteins were highly expressed in HSR-GBM1 cells. This
is consistent with the results of lectin microarray, where both
TKA and PNA showed higher binding capacity to HSR-GBM1
cells than to U373 cells (Figure 2). Figure 5 shows heat maps
based on the spectral counts of differentially expressed glyco-
proteins enriched by TKA (Figure 5A) and PNA (Figure 5B) from
HSR-GBM1 and U373 cells. In this figure, protein abundance
increased from red to blue color. The differential expression
of these proteins was remarkable between the two cell lines.
Hierarchical clustering revealed good correlation between each
experimental replicate.
Western Blotting Analysis of Selected Proteins. To make
the previous results more confident, we applied Western
blotting analysis to evaluate the changes of a suite of differ-
entially expressed glycoproteins (Figure 6). To verify that these
changes were universal between the HSR-GBM1 glioblastoma-
derived stem-like cells and the GBM cells from traditional
cultured adherent cell lines, we selected four cell lines including
the HSR-GBM1 neurosphere line and three human GBM cell
lines U373, U87, and T98G. Five glycoproteins including
Podocalyxin-like protein 1 (PODXL), Chondroitin sulfate pro-
teoglycan NG2 (NG2), Tenascin-C (TNC), Receptor-type ty-
rosine-protein phosphatase zeta (PTPRZ1), and CD90 were
expressed at much higher levels in the HSR-GBM1 neurosphere
cell line than in the three adherent GBM cell lines. CD44
antigen was undetectable in the HSR-GBM1 neurosphere cell
line, while it was highly expressed in all of the other three cell
lines (Figure 6). The trends in expression of all of the six
proteins shown in Figure 6 were consistent with the previous
MS results shown in Tables 2 and 3.
Noteworthy, PTPRZ1 was detected only in the HSR-GBM1
neurosphere cells, as shown in Figure 6. Similar to our results,
Figure 4. Subcellular location of glycoproteins identified from
HSR-GBM1 and U373 cells after TKA and PNA enrichment.
Table 2. Differentially Expressed Glycoproteins from TKA Captured Fractions
accession protein name gene location ratioa p-valueb
IPI00022462 CD71 antigen TFRC membrane 12.89 0.0011
IPI00748312 Receptor-type tyrosine-protein phosphatase zeta PTPRZ1 membrane NAc 0.0019
IPI00027230 Endoplasmin HSP90B1 ER 2.78 0.0020
IPI00299116 Podocalyxin-like protein 1 PODXL membrane NA 0.0033
IPI00027493 CD98 antigen SLC3A2 membrane 0.15 0.0058
IPI00022892 CD90 antigen THY1 membrane NA 0.0074
IPI00297160 CD44 antigen CD44 membrane 0 0.011
IPI00022463 Serotransferrin TF extracellular NA 0.019
IPI00031008 Tenascin-C TNC extracellular NA 0.023
IPI00217563 CD29 antigen ITGB1 membrane 0 0.039
IPI00019275 CD276 antigen CD276 membrane NA 0.045
IPI00019157 Chondroitin sulfate proteoglycan NG2 CSPG4 membrane NA 0.045
a The ratio of the spectral count of a target protein identified from HSR-GBM1 cells to that identified from U373 cells. b P-value: statistical significance
of differentially expressed proteins between HSR-GBM1 and U373 cells. The values were generated by Student’s t-test for three independent experiments.
c NA means the protein was only identified from HSR-GBM1 cells.
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PTPRZ1 was highly expressed in the undifferentiated embryonic
stem cells compared with differentiated cells.35 PTPRZ1 was
also found to be overexpressed in human glioblastomas
compared to normal brains, and a knockdown study of this
protein established its function in regulating cell motility.36
Therefore, the overexpression of PTPRZ1 in cancer stem-like
cells may play important roles in cell migration and cancer
metastasis.
PTPRZ1 has been found to interact with a glycoprotein
Tenascin-C in vivo.37,38 Tenascin-C was originally discovered
as a glioma-mesenchymal extracellular matrix antigen that is
ubiquitously expressed in glioblastomas but not in normal
brains.39 In a recent work, this protein has been identified as
a novel target gene for Notch signaling in GBM.40 Tenascin-C
contributes to the generation of a stem cell niche, which is
important to the development of neural stem cells.41,42 In the
present work, the overexpression of Tenascin-C in the HSR-
GBM1 neurosphere cell line compared to the other three
adherent GBM cell lines (Figure 6) indicates that the protein is
mainly expressed in the stem-like cells in GBM. Tenascin-C
has previously been shown to interact with Chondroitin sulfate
proteoglycan NG2,43 which was also highly expressed in the
HSR-GBM1 cells (Figure 6). NG2 has been widely used as a
marker of multiponent neural progenitor cells.44-46
The interactions among PTPRZ1, Tenascin-C, and NG2 may
play important roles in the development and metastasis of
Table 3. Differentially Expressed Glycoproteins from PNA Captured Fractions
accession protein name gene location ratioa p-valueb
IPI00299116 Podocalyxin-like protein 1 PODXL membrane NAc 0.00005
IPI00748312 Receptor-type tyrosine-protein phosphatase zeta PTPRZ1 membrane NA 0.00027
IPI00031131 Adipocyte plasma membrane-associated protein APMAP membrane NA 0.00089
IPI00005707 CD280 antigen MRC2 membrane NA 0.00096
IPI00215998 CD63 antigen CD63 membrane NA 0.0015
IPI00022892 CD90 antigen THY1 membrane NA 0.0016
IPI00019906 CD147 antigen BSG membrane NA 0.0023
IPI00019157 Chondroitin sulfate proteoglycan NG2 CSPG4 membrane NA 0.0027
IPI00025874 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase
subunit 1
RPN1 ER NA 0.0036
IPI00022462 CD71 antigen TFRC membrane 6.10 0.021
IPI00004656 Beta-2-microglobulin B2M extracellular 0 0.029
a The ratio of the spectral count of a target protein identified from HSR-GBM1 cells to that identified from U373 cells. b P-value: statistical significance
of differentially expressed proteins between HSR-GBM1 and U373 cells. The values were generated by Student’s t-test for three independent experiments.
c NA means the protein was only identified from HSR-GBM1 cells.
Figure 5. Heat maps with dendrograms of hierarchical clustering for triplicate experiments. The heat maps were based on the spectral
counts of differentially expressed glycoproteins identified from TKA (A) and PNA (B) enriched fractions of HSR-GBM1 and U373 cells.
Each column indicates an independent experiment of each cell line, and each row indicates a glycoprotein identified by LC-MS/MS.
The number of spectral count increased from red color to blue color. The Pearson correlation coefficients were indicated at each
branching point. Both of the heat maps were generated with R language. GBM1 represents HSR-GBM1.
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GBM. These glycoproteins may be used as markers for GBM
stem-like cells, and they may be targeted for drug treatment
of GBM patients. An anti-Tenascin monoclonal antibody has
been studied for clinical treatment of malignant brain tumors.47
PTPRZ1 and NG2 may also be used for the similar clinical
studies.
The changes of three other glycoproteins Podocalyxin-like
protein 1, CD90, and CD44 were also confirmed by Western
blotting analysis. Podocalyxin-like protein 1 belongs to the
CD34 family, and it has been used as a marker of embryonic
and hematopoietic stem cells.48,49 CD90 has been identified
as a marker of cancer stem cells in human liver cancer.50 CD44
is the receptor for hyaluronic acid, and it has been used to
fractionate cancer stem-like cells from several kinds of solid
tumors including breast,51 head and neck,52 pancreatic,53 and
colorectal54 cancers. However, this protein was not detectable
in the GBM-derived stem-like cells in our work (Figure 6).
Conclusions
We employed a method combining lectin microarray and
LC-MS/MS to discover the cell surface glycoprotein markers
of a GBM-derived cancer stem-like cell line. The cell surface
glycan expression patterns of a GBM-derived stem-like neu-
rosphere line HSR-GBM1 and a traditional adherent GBM cell
line U373 were first explored by lectin microarrays consisting
of 16 lectins. Two galactose-specific lectins TKA and PNA
showed much stronger binding capacity to HSR-GBM1 neu-
rosphere cells than to U373 cells, indicating higher expression
of galactosylated glycoproteins on the surface of GBM stem-
like cells. Agarose-bound TKA and PNA were then used to
capture the glycoproteins of the two cell lines by affinity
chromatography, followed by protein identification by LC-MS/
MS and quantification by spectral counting. Consequently, 12
differentially expressed glycoproteins between HSR-GBM1 and
U373 cells were identified from the TKA enriched fractions, and
11 were identified from the PNA enriched fractions. Of these
proteins, 5 were overlapped, making it a total of 18 differentially
expressed glycoproteins. The changes of six interesting glyco-
proteins were further verified by Western blotting analysis using
four cell lines including the HSR-GBM1 neurosphere line and
three adherent GBM cell lines U373, U87, and T98G. These
proteins include the overexpressed Receptor-type tyrosine-
protein phosphatase zeta, Tenascin-C, Chondroitin sulfate
proteoglycan NG2, Podocalyxin-like protein 1 and CD90, and
the down-regulated CD44. A better understanding of these
proteins may bring an exciting opportunity for identifying
markers for cancer stem-like cells in GBM.
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